<table><thead><tr class="rowsep-1 valign-top"><th scope="col"></th><th scope="col"></th><th scope="col">n</th><th scope="col">ntEVNs</th><th scope="col">n</th><th scope="col">mtEVNs</th></tr></thead><tbody><tr><th rowspan="3" scope="row">Demographics</th><td>Age (mean)</td><td rowspan="3">14</td><td>35.5 years</td><td rowspan="3">6</td><td>19.7 years</td></tr><tr><td>Female</td><td>50%</td><td>17%</td></tr><tr><td>Male</td><td>50%</td><td>83%</td></tr><tr><th rowspan="2" scope="row">Tumor lateralization</th><td>Right</td><td rowspan="2">14</td><td>64%</td><td rowspan="2">6</td><td>50%</td></tr><tr><td>Left</td><td>36%</td><td>50%</td></tr><tr><th rowspan="6" scope="row">Radiographic features</th><td>Cystic changes</td><td rowspan="6">12</td><td>33%</td><td rowspan="6">6</td><td>0%</td></tr><tr><td>Mass effect</td><td>33%</td><td>33%</td></tr><tr><td>Perilesional edema</td><td>11%</td><td>0%</td></tr><tr><td>Hypointense on T1</td><td>44%</td><td>50%</td></tr><tr><td>Hyperintense on T2</td><td>100%</td><td>100%</td></tr><tr><td>Contrast enhancing</td><td>56%</td><td>17%</td></tr><tr><th rowspan="5" scope="row">Histology</th><td>Hypervascular</td><td rowspan="2">9</td><td>33%</td><td rowspan="2">2</td><td>0%</td></tr><tr><td>Hypovascular</td><td>11%</td><td>100%</td></tr><tr><td>Calcifications</td><td>5</td><td>80%</td><td>3</td><td>0%</td></tr><tr><td>Mitoses (≥ 1/HPF)</td><td rowspan="2">8</td><td>100%</td><td rowspan="2">1</td><td>0%</td></tr><tr><td>Necrosis</td><td>0%</td><td>0%</td></tr><tr><th rowspan="6" scope="row">Immunohistochemistry</th><td>Syn (+)</td><td>12</td><td>100%</td><td>5</td><td>100%</td></tr><tr><td>GFAP (+)</td><td>6</td><td>83%</td><td>3</td><td>67%</td></tr><tr><td>NF</td><td>2</td><td>50%</td><td>1</td><td>100%</td></tr><tr><td>NSE</td><td>2</td><td>100%</td><td colspan="2">No studies</td></tr><tr><td>NeuN</td><td colspan="2">No studies</td><td>3</td><td>100%</td></tr><tr><td>MAP-2</td><td>1</td><td>100%</td><td>1</td><td>100%</td></tr><tr><th rowspan="2" scope="row">Surgical condition</th><td>STR</td><td rowspan="2">13</td><td>31%</td><td rowspan="2">4</td><td>0%</td></tr><tr><td>GTR</td><td>69%</td><td>100%</td></tr><tr><th scope="row">Adjuvant therapy</th><td>Radiation</td><td>9</td><td>33%</td><td>4</td><td>0%</td></tr><tr><th rowspan="2" scope="row">Outcome</th><td>Length of follow-up (mean)</td><td rowspan="2">13</td><td>22.4 months</td><td rowspan="2">5</td><td>11.2 months</td></tr><tr><td>NED</td><td>77%</td><td>100%</td></tr></tbody></table>